CD157-Positive Endothelial Cell Therapy for Brain Vessel Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic cerebral hypoperfusion, which is associated with conditions such as white matter lesions and cognitive decline, are not clinically effective, and there is a lack of specific treatments for regenerating brain blood vessels.
Innovation Solution
A medicament comprising vascular endothelial cells positive for the CD157 cell surface marker, derived from mammals, is administered to the brain to regenerate brain blood vessels and treat conditions associated with decreased brain blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional non-specific therapies (risk factor management, lifestyle-related disease treatment) are used for chronic cerebral hypoperfusion, then general health may be improved, but specific therapeutic effect on brain blood flow and cognitive functions is not achieved
Solution Approach 1:
The patent extracts and isolates a specific cell population (CD157-positive vascular endothelial cells) from the complex system of vascular endothelial cells. This extraction allows for targeted therapy that specifically addresses chronic cerebral hypoperfusion and white matter lesions, rather than using general risk factor management. The isolated cell type can be administered directly to achieve specific therapeutic effects on brain blood flow and cognitive functions.
2Object-affected harmful factors
If pharmacological approaches (minocycline, cilostazol, edaravone) are administered, then some symptomatic relief may be achieved, but regeneration of brain blood vessels is not accomplished
Solution Approach 1:
The patent uses CD157-positive vascular endothelial cells as an intermediary to bridge the gap between symptomatic relief and actual vascular regeneration. These cells serve as living mediators that can both alleviate symptoms through improved blood flow and actively regenerate damaged blood vessels through their stem cell capacity and ability to form new vascular structures in the brain.
3Ease of operation
If rehabilitation approaches (brain reperfusion rehabilitation therapy) are used, then functional improvement may occur, but the underlying vascular damage is not repaired
Solution Approach 1:
The patent applies preliminary action by administering CD157-positive vascular endothelial cells before significant irreversible damage occurs. These cells prepare and repair the vascular structure in advance, creating a foundation that supports subsequent functional recovery. The regenerative action of the transplanted cells strengthens the vascular structure proactively, rather than merely responding to established damage.
4Reliability
If transplantation of human umbilical cord-derived mesenchymal stem cells is performed, then some regenerative effect may be achieved, but targeted regeneration of brain blood vessels is not realized
Solution Approach 1:
The patent applies local quality by using a specific subset of vascular endothelial cells (CD157-positive) that possess unique properties for brain vascular regeneration. Rather than using generic mesenchymal stem cells, this approach targets the specific local need for endothelial cell regeneration in the brain's vascular system. The CD157-positive cells are locally adapted to the brain environment and can specifically regenerate brain blood vessels with high efficiency.
Data Source
Figure 1(A)~1(C)
Figure 2(A)~2(D)
Figure 3~4(B)
AI summary
The present invention provides a medicament for preventing and/or treating a disease or condition associated with a decrease in brain blood flow, comprising vascular endothelial cells positive for a CD157 cell surface marker, wherein the cells are from a mammal, wherein the medicament is used so that the vascular endothelial cells are delivered into a brain; and a medicament for regenerating brain blood vessels, comprising vascular endothelial cells positive for a CD157 cell surface marker, wherein the cells are from a mammal, wherein the medicament is used so that the vascular endothelial cells are delivered into a brain.